Galapagos Licenses MetaCore From GeneGo

GeneGo, Inc. has announced that Galapagos NV will be using the integrated software suite MetaCore for its internal research across several disease areas including osteoporosis, osteoarthritis and rheumatoid arthritis.

"We were satisfied with the demonstrated capabilities and quality of data obtained through MetaCore," commented Dr. Graham Dixon, Senior Vice President of Drug Discovery at Galapagos.

"We have already identified and validated novel, proprietary targets using our adenoviral technology platform in bone and joint diseases; applying MetaCore to this target set could allow us to gain valuable insights at the system level thereby improving our understanding of the underlying disease biology and increasing our speed and success in finding new drugs against these targets."

"We are very pleased to welcome Galapagos as a new customer," said Julie Bryant, Vice President of Business Development at GeneGo.

"Over the last year, systems analysis of biological data has become mainstream, rather than a niche application, for high volume high throughput genomics labs."

"The new customization tools and expansion of knowledge content in disease areas make MetaCore applicable for focused research programs at specialized drug discovery companies."

"We are proud that Galapagos has selected MetaCore in the competitive market of pathways tools."